Oncology (all articles)
Consensus Paper | Diagnosis and treatment of anticancer drug-induced interstitial lung disease
29 Mar, 2023 | 13:04h | UTC
ChatGPT vs. NCI: analyzing the quality of cancer information on myths and misconceptions
28 Mar, 2023 | 15:00h | UTCNews Release: Looking for cancer information: Can ChatGPT be counted on? – Huntsman Cancer Institute
Consensus Statement | Management of vaginal intraepithelial neoplasia
28 Mar, 2023 | 14:37h | UTC
Review | Systemic therapy in HR+/HER2- early stage & metastatic breast cancer management
28 Mar, 2023 | 14:34h | UTC
Expanding Organ Usage: UK study finds organs from patients with a primary brain tumor are a viable option
27 Mar, 2023 | 13:27h | UTCSummary: A national cohort study in the UK investigated the risk of cancer transmission from deceased donors with primary brain tumors to organ recipients. The study found no cases of brain tumor transmission among 778 transplants from 282 donors with primary brain tumors, including 262 from donors with high-grade tumors. Organ transplant survival was equivalent to that in matched controls, and some organs from donors with high-grade tumors were less likely to be transplanted.
The results suggest that the risk of cancer transmission in transplants from deceased donors with primary brain tumors is lower than previously thought. Furthermore, the study indicated that donors with brain tumors provided good-quality organs with favorable risk markers and excellent transplant outcomes. Some organs from donors with high-grade tumors were underutilized, indicating a possible aversion by transplant clinicians or patients to use these organs.
These findings imply that it may be possible to safely expand organ usage from donors with primary brain tumors without negatively impacting outcomes, potentially benefiting many patients waiting for a transplant. Although this might lead to a slight rise in transplant numbers in the UK, the findings may hold particular significance for nations with stricter guidelines, such as the United States. The study’s findings can help transplant clinicians discuss the risks and benefits of accepting organ offers from such donors.
Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study
27 Mar, 2023 | 13:12h | UTCOutcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study – European Heart Journal – Quality of Care and Clinical Outcomes (free for a limited period)
Commentary on Twitter
Cancer and #STEMI – a worrisome combination of higher short- and long-term mortality, and bleeding risk. https://t.co/kHvhGP0PBE #EHJQCCO #cardiotwitter @cpgale3 @diogoasantosfer pic.twitter.com/SfjyizoJvQ
— European Society of Cardiology Journals (@ESC_Journals) March 26, 2023
Review | Neoadjuvant therapy for pancreatic cancer
27 Mar, 2023 | 13:02h | UTCNeoadjuvant therapy for pancreatic cancer – Nature Reviews Clinical Oncology (free for a limited period)
Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy
23 Mar, 2023 | 13:11h | UTCSummary: This study investigated the association between estimated life expectancy, surveillance colonoscopy findings, and follow-up recommendations among older adults. The study utilized data from the New Hampshire Colonoscopy Registry and included adults over 65 who underwent colonoscopy for surveillance after prior polyps.
Life expectancy was estimated using a validated prediction model and categorized into three groups: less than 5 years, 5 to less than 10 years, and 10 or more years.
Out of the 9,831 adults included in the study, 8% had advanced polyps or CRC. Among the 5,281 patients with available recommendations, 86.9% were advised to return for a future colonoscopy. Surprisingly, 58.1% of older adults with less than 5 years of life expectancy were also recommended to return for future surveillance colonoscopy.
The study concluded that many older adults with limited life expectancy are still recommended for future surveillance colonoscopy. This data could help refine decision-making about pursuing or stopping surveillance colonoscopy in older adults with a history of polyps.
Article: Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults – JAMA Internal Medicine (link to abstract – $ for full-text)
JAMA Patient Page: What Should I Know About Stopping Routine Cancer Screening?
Commentary on Twitter
Findings suggest that recommending against future surveillance colonoscopy in older adults with low-risk colonoscopy findings and/or limited life expectancy should be considered more frequently than is currently practiced. https://t.co/7jKpYyuZON
— JAMA Internal Medicine (@JAMAInternalMed) March 13, 2023
Guideline | Merkel cell carcinoma
23 Mar, 2023 | 12:48h | UTC
Guidelines for Gastric Cancer | An evidence-based, multidisciplinary approach
22 Mar, 2023 | 13:33h | UTC
Guidelines for post polypectomy colonoscopic surveillance
22 Mar, 2023 | 13:31h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
RCT | Comparable 5-year relapse-free survival for laparoscopic vs. open distal gastrectomy in advanced gastric cancer
22 Mar, 2023 | 13:27h | UTCSummary: The JLSSG0901 randomized clinical trial aimed to compare the 5-year survival outcomes of laparoscopy-assisted distal gastrectomy (LADG) and open distal gastrectomy (ODG) with D2 lymph node dissection for locally advanced gastric cancer.
The study involved 507 patients from 37 institutes in Japan. The primary endpoint was 5-year relapse-free survival. The results showed that the 5-year relapse-free survival rates were 73.9% and 75.7% for the ODG and LADG groups, respectively, confirming the noninferiority of LADG, and no significant differences were observed in severe postoperative complications between the two groups.
The study concluded that LADG with D2 lymph node dissection, when performed by qualified surgeons, was proven noninferior to ODG, and could become a standard treatment for locally advanced gastric cancer.
Article: Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Related:
Commentary on Twitter
Study results provide robust evidence suggesting that laparoscopic gastrectomy for locally advanced gastric cancer may be an appropriate treatment approach when performed by skilled surgeons. https://t.co/Dvnzk5YI9u pic.twitter.com/GDCdT4DJhp
— JAMA Surgery (@JAMASurgery) March 15, 2023
RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma
22 Mar, 2023 | 13:12h | UTCHyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources
21 Mar, 2023 | 13:29h | UTC
Guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease)
21 Mar, 2023 | 13:27h | UTC
Opinion | Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival
20 Mar, 2023 | 13:45h | UTC
RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation
20 Mar, 2023 | 13:10h | UTCSotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Docetaxel is the recommended treatment for non-small-cell lung cancer (NSCLC) at disease progression, but it has shown modest clinical benefit.
The CodeBreaK 200 trial compares the KRAS inhibitor sotorasib with docetaxel in patients with advanced NSCLC.https://t.co/Sk7Rk1lAl2
— The Lancet (@TheLancet) March 9, 2023
FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants
16 Mar, 2023 | 13:28h | UTCSummary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.
While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.
The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.
FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration
Related:
FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma
Study: Long-term Outcomes of Silicone Breast Implants
M-A | Low-intensity follow-up after cancer surgery does not reduce patient satisfaction or well-being
16 Mar, 2023 | 13:10h | UTCOncological surgery follow-up and quality of life: meta-analysis – British Journal of Surgery
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
15 Mar, 2023 | 15:24h | UTCSummary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.
The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.
The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.
Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence
Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer
15 Mar, 2023 | 15:11h | UTC
RCT | Nirogacestat for desmoid tumors
15 Mar, 2023 | 14:57h | UTCNirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Nirogacestat Improves Outcomes for Patients With Desmoid Tumors – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In a randomized, placebo-controlled trial, oral nirogacestat twice daily led to 41% of patients having a tumor response, and 2-year progression-free survival was 76%. Most adverse events were low grade. https://t.co/wtt7solTHW pic.twitter.com/qkRchfnXU2
— NEJM (@NEJM) March 10, 2023
Review | Surveillance strategies following curative resection and non-operative approach of rectal cancer: how and how long?
15 Mar, 2023 | 14:59h | UTC
M-A | Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer
15 Mar, 2023 | 14:52h | UTCRelated:
Cohort Study | Higher ultra-processed food consumption linked to increased cancer incidence and mortality
15 Mar, 2023 | 14:48h | UTCNews Release: Ultra-processed foods may be linked to increased risk of cancer – Imperial College London
Related: